[ad_1]
Lab technicians work on the manufacturing of anti-Covid drug molnupiravir in southern Binh Duong province, Feb. 23, 2022. Picture by VnExpress/Quynh Tran
Demand for Covid-19 medicines and different gadgets drove pharmaceutical corporations’ earnings up within the first quarter.
The nation’s largest drugmaker, DHG Pharmaceutical JSC, reported a 25 p.c leap in earnings to VND255 billion (US$11.1 million), its highest since 2005.
Traphaco JSC’s earnings rose by 55 p.c to VND83 billion, and Imexpharm JSC’s by 26 p.c to VND52.6 billion.
Different drug firms additionally reported double-digit will increase in earnings.
DHG Pharmaceutical reported large demand for Covid medicines resembling klamentin, medlon and bocalex, whereas the Traphaco administration stated cough medicines and mouthwashes had been amongst its high sellers.
Domesco Medical Import Export JSC attributed its 32 p.c progress within the first quarter to new Covid prevention and long-Covid therapy merchandise.
Main brokerage SSI Securities stated the healthcare market would surpass pre-pandemic ranges by way of measurement this 12 months.
It anticipated gentle Covid therapy merchandise resembling fever medication and nutritional vitamins to be high promoting merchandise due to Vietnam’s excessive vaccination price and fewer extreme variants.
Pharmaceutical corporations are anticipated to prosper till mid-2022 no less than, it added.
Costs may rise barely within the close to future since China would possibly tighten insurance policies on energetic pharmaceutical ingredient (API) manufacturing to guard the surroundings, driving uncooked materials costs up.
China accounted for 44 p.c of API manufacturing in 2019, in accordance with a report by Indian monetary establishment ICICI.
[ad_2]
Source link